Innovent Biologics Future Growth
Future criteria checks 5/6
Innovent Biologics is forecast to grow earnings and revenue by 59.4% and 22.2% per annum respectively. EPS is expected to grow by 60.2% per annum. Return on equity is forecast to be 16% in 3 years.
Key information
59.4%
Earnings growth rate
60.2%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 22.2% |
| Future return on equity | 16.0% |
| Analyst coverage | Good |
| Last updated | 24 Sep 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13,612 | 1,345 | 1,363 | N/A | 27 |
| 12/31/2025 | 10,539 | 69 | -226 | N/A | 29 |
| 12/31/2024 | 8,022 | -814 | -1,329 | N/A | 29 |
| 6/30/2024 | 7,457 | -1,281 | N/A | N/A | N/A |
| 3/31/2024 | 6,831 | -1,155 | N/A | N/A | N/A |
| 12/31/2023 | 6,206 | -1,028 | -1,234 | 148 | N/A |
| 9/30/2023 | 5,612 | -1,198 | -2,241 | -794 | N/A |
| 6/30/2023 | 5,018 | -1,368 | -3,249 | -1,735 | N/A |
| 3/31/2023 | 4,787 | -1,774 | -3,267 | -1,827 | N/A |
| 12/31/2022 | 4,556 | -2,179 | -3,284 | -1,919 | N/A |
| 9/30/2022 | 4,562 | -2,427 | -3,507 | -1,867 | N/A |
| 6/30/2022 | 4,568 | -2,676 | -3,729 | -1,816 | N/A |
| 3/31/2022 | 4,419 | -2,702 | -3,801 | -1,920 | N/A |
| 12/31/2021 | 4,270 | -2,729 | -3,872 | -2,025 | N/A |
| 9/30/2021 | 4,536 | -2,061 | -2,660 | -1,302 | N/A |
| 6/30/2021 | 4,801 | -1,394 | -1,447 | -580 | N/A |
| 3/31/2021 | 4,323 | -1,196 | -1,138 | -444 | N/A |
| 12/31/2020 | 3,844 | -998 | -829 | -308 | N/A |
| 9/30/2020 | 2,765 | -1,306 | -1,307 | -900 | N/A |
| 6/30/2020 | 1,686 | -1,614 | -1,784 | -1,492 | N/A |
| 3/31/2020 | 1,367 | -1,667 | -1,907 | -1,578 | N/A |
| 12/31/2019 | 1,048 | -1,720 | -2,030 | -1,664 | N/A |
| 9/30/2019 | 699 | -4,125 | -1,988 | -1,625 | N/A |
| 6/30/2019 | 351 | -6,530 | -1,945 | -1,586 | N/A |
| 3/31/2019 | 180 | -6,151 | -1,635 | -1,299 | N/A |
| 12/31/2018 | 9 | -5,771 | -1,325 | -1,012 | N/A |
| 9/30/2018 | 39 | -3,041 | -1,046 | -799 | N/A |
| 6/30/2018 | 69 | -311 | -767 | -587 | N/A |
| 3/31/2018 | 72 | -437 | N/A | -540 | N/A |
| 12/31/2017 | 75 | -562 | N/A | -492 | N/A |
| 12/31/2016 | 29 | -504 | N/A | -363 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IVBX.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).
Earnings vs Market: IVBX.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IVBX.F is expected to become profitable in the next 3 years.
Revenue vs Market: IVBX.F's revenue (22.2% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: IVBX.F's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IVBX.F's Return on Equity is forecast to be low in 3 years time (16%).